Genome-wide association studies have revealed genomic regions associated with more than 200 diseases, including heart disease, diabetes and different types of cancer. The unveiled human genetic variation has attracted much attention in both scientific and popular press. However, the mechanisms by which these genomic regions act are not fully understood. One suggestion that has generated considerable interest is the possibility that the risk polymorphisms located far from genes could function as gene regulatory elements or “switches” that regulate the expression of genes.
In the current study, which was conducted in mice, scientists have analyzed one particular single nucleotide variant in a region associated with increased risk for developing colorectal and prostate cancers, but whose mechanism of action has been unclear. Although this variant increases cancer risk only by 20 per cent, it is very common and therefore accounts for more inherited cancer than any other currently known genetic variant or mutation.
The scientists removed the gene region containing the risk variant from the mouse genome, and found that as a result the mice were healthy but displayed a small decrease in the expression of a nearby cancer gene, called MYC. However, when these mice were tested for the ability to form tumours after activation of an oncogenic signal that causes colorectal cancer in humans, they showed dramatic resistance to tumor formation. The removed gene region thus appears to act as an important gene switch promoting cancer, and without it tumors develop much more rarely.
According to the scientists, these results show that although the gene variants – which make individual humans different from each other – in general have a small impact on disease development, the gene switches in which they reside can play a major role.
“Our study also highlights that growth of normal cells and cancer cells is driven by different gene switches, suggesting that further work to find ways to control the activity of such disease-specific switches could lead to novel, highly specific approaches for therapeutic intervention”, says Professor Jussi Taipale, who led the study.
The work was supported by the Center for Biosciences at Karolinska Institutet, the Karolinska University Hospital, the Science for Life Laboratory, the Academy of Finland’s Center of Excellence in Cancer Genetics Research, the Swedish Research Council, the Swedish Cancer Foundation, the European Research Council, and the EU FP7 Health project SYSCOL.
Publication: “Mice Lacking a Myc Enhancer Element that Includes Human SNP rs6983267 Are Resistant to Intestinal Tumors”, Sur, I., Hallikas, O., Vähärautio, A., Yan, J., Turunen, M., Enge, M., Taipale, M., Karhu, A., Aaltonen, L. A., and Taipale, J., Science, in press, online 1 November 2012.
Journal website: www.sciencemag.org
Science for Life Laboratory: www.scilifelab.se
Karolinska Institutet is one of the world’s leading medical universities. It accounts for over 40 per cent of the medical academic research conducted in Sweden and offers the country’s broadest range of education in medicine and health sciences. Since 1901 the Nobel Assembly at Karolinska Institutet has selected the Nobel laureates in Physiology or Medicine.